Mitsubishi UFJ Trust & Banking Corp decreased its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 62.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,139 shares of the specialty pharmaceutical company’s stock after selling 75,936 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned about 0.07% of Jazz Pharmaceuticals worth $7,589,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in JAZZ. Credit Suisse AG grew its stake in shares of Jazz Pharmaceuticals by 2.4% during the 3rd quarter. Credit Suisse AG now owns 93,239 shares of the specialty pharmaceutical company’s stock worth $15,675,000 after purchasing an additional 2,158 shares during the period. DekaBank Deutsche Girozentrale grew its stake in shares of Jazz Pharmaceuticals by 3.4% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 26,607 shares of the specialty pharmaceutical company’s stock worth $4,607,000 after purchasing an additional 884 shares during the period. BlackRock Inc. grew its stake in shares of Jazz Pharmaceuticals by 2.7% during the 3rd quarter. BlackRock Inc. now owns 4,490,714 shares of the specialty pharmaceutical company’s stock worth $755,024,000 after purchasing an additional 118,634 shares during the period. Martingale Asset Management L P grew its stake in shares of Jazz Pharmaceuticals by 10,786.8% during the 3rd quarter. Martingale Asset Management L P now owns 174,516 shares of the specialty pharmaceutical company’s stock worth $29,342,000 after purchasing an additional 172,913 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Jazz Pharmaceuticals by 14.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,690,385 shares of the specialty pharmaceutical company’s stock worth $284,205,000 after purchasing an additional 207,954 shares during the period. Hedge funds and other institutional investors own 91.53% of the company’s stock.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,300 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $167.99, for a total transaction of $218,387.00. Following the sale, the chief executive officer now directly owns 279,915 shares of the company’s stock, valued at approximately $47,022,920.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $165.20, for a total transaction of $33,040.00. Following the sale, the executive vice president now directly owns 25,372 shares in the company, valued at $4,191,454.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 6,600 shares of company stock worth $1,063,472. 3.90% of the stock is owned by corporate insiders.
A number of equities analysts have recently weighed in on the stock. BidaskClub cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Mizuho lowered their price target on shares of Jazz Pharmaceuticals to $157.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 20th. Zacks Investment Research reaffirmed a “hold” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, November 13th. HC Wainwright reaffirmed a “hold” rating and set a $161.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, November 14th. Finally, Piper Jaffray Companies set a $208.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, November 7th. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $189.76.
Shares of NASDAQ JAZZ opened at $141.17 on Friday. The stock has a market capitalization of $8.66 billion, a P/E ratio of 12.42, a price-to-earnings-growth ratio of 0.86 and a beta of 0.94. Jazz Pharmaceuticals PLC has a 52 week low of $130.15 and a 52 week high of $184.00. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.16 and a current ratio of 4.29.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 EPS for the quarter, beating the Zacks’ consensus estimate of $3.32 by $0.26. The firm had revenue of $469.37 million for the quarter, compared to analysts’ expectations of $482.64 million. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The firm’s revenue was up 14.0% on a year-over-year basis. During the same period in the prior year, the company earned $3.22 EPS. As a group, equities research analysts expect that Jazz Pharmaceuticals PLC will post 11.6 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2018/12/08/mitsubishi-ufj-trust-banking-corp-trims-position-in-jazz-pharmaceuticals-plc-jazz.html.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Further Reading: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.